Skip to main content

Table 3 Diagnostic accuracy of PET/MRI findings for cardiac sarcoidosis

From: Combined simultaneous FDG-PET/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis

 

Sensitivity (95% CI)

Specificity (95% CI)

Positive predictive value (95% CI)

Negative predictive value (95% CI)

Area under the curve (95% CI)

All patients (n = 42)

FDG-PET positive (PET+)

69 (39, 91)

69 (49, 85)

50 (26, 74)

83 (63, 95)

0.69 (0.54, 0.85)

LGE presence

100 (75, 100)

31 (15, 51)

39 (23, 58)

100 (66, 100)

0.66 (0.66, 0.74)

High native T1

100 (75, 100)

39 (22, 59)

43 (26, 63)

100 (72, 100)

0.70 (0.60, 0.79)

High ECV

100 (75, 100)

39 (22, 59)

43 (26, 63)

100 (72, 100)

0.70 (0.60, 0.79)

High native T2

46 (19, 75)

79 (59, 92)

50 (21, 79)

76 (57, 90)

0.62 (0.46, 0.78)

Updated Lake Louise criteria

46 (19, 75)

79 (59, 92)

50 (21, 79)

76 (57, 90)

0.62 (0.46, 0.78)

MRI positive (MRI+)

100 (75, 100)

31 (15, 51)

39 (23, 58)

100 (66, 100)

0.66 (0.66, 0.74)

Combined PET/MRI (PET+ and/or MRI+)

100 (75, 100)

28 (13, 47)

38 (22, 56)

100 (63, 100)

0.64 (0.56, 0.72)

Co-localized focal FDG uptake and LGE

69 (39, 91)

76 (57, 90)

56 (30, 80)

85 (65, 96)

0.73 (0.57, 0.88)

Co-localized focal FDG uptake and high T1

69 (39, 91)

76 (57, 90)

56 (30, 80)

85 (65, 96)

0.73 (0.57, 0.88)

Co-localized focal FDG uptake and high T2

46 (19, 75)

83 (64, 94)

55 (23, 83)

77 (59, 90)

0.65 (0.49, 0.80)

Patients not treated with immune suppression therapy (n = 36)

FDG-PET positive (PET+)

73 (39, 94)

72 (51, 88)

53 (27, 79)

86 (64, 97)

0.72 (0.56, 0.89)

LGE presence

100 (72, 100)

32 (15, 54)

39 (22, 59)

100 (63, 100)

0.66 (0.57, 0.75)

High native T1

100 (72, 100)

38 (15, 54)

39 (22, 59)

100 (63, 100)

0.66 (0.57, 0.75)

High ECV

100 (72, 100)

38 (15, 54)

39 (22, 59)

100 (63, 100)

0.66 (0.57, 0.75)

High native T2

46 (17, 77)

75 (53, 90)

46 (17, 77)

75 (53, 90)

0.60 (0.42, 0.78)

Updated Lake Louise criteria

46 (17, 77)

75 (53, 90)

46 (17, 77)

75 (53, 90)

0.60 (0.42, 0.78)

MRI positive (MRI+)

100 (72, 100)

24 (9, 45)

37 (20, 56)

100 (54, 100)

0.62 (0.54, 0.71)

Combined PET/MRI (PET+ and/or MRI+)

100 (72, 100)

28 (12, 49)

38 (21, 58)

100 (59, 100)

0.64 (0.55, 0.73)

Co-localized focal FDG uptake and LGE

73 (39, 94)

76 (55, 91)

57 (29, 82)

86 (65, 97)

0.74 (0.58, 0.91)

Co-localized focal FDG uptake and high T1

73 (39, 94)

76 (55, 91)

57 (29, 82)

86 (65, 97)

0.74 (0.58, 0.91)

Co-localized focal FDG uptake and high T2

46 (17, 77)

80 (59, 93)

50 (19, 81)

77 (56, 91)

0.63 (0.45, 0.80)

  1. 95% confidence intervals (CI) are in parentheses. Final diagnosis of cardiac sarcoidosis was established using modified 2006 revised Japanese Ministry of Health and Welfare (JMHW) guideline as the reference standard
  2. PET Positron emission tomography, LGE late gadolinium enhancement, ECV extracellular volume, MRI magnetic resonance imaging, ROC receiver operating characteristic
  3. PET was considered positive (+) if the pattern of FDG uptake was focal or focal on diffuse. MRI was considered positive (+) if LGE was present or if native T1, T2 or ECV were elevated